A Business at a Glance
0 of 1 daily views used (1 remaining). Sign up free for +5 more daily views (6 total), or try AAPL for a full preview.
Dianthus Therapeutics, Inc. /DE/
DNTH
$4.0B
Mkt Cap
$103.87
-0.88%
Dianthus Therapeutics, Inc. /DE/ (DNTH) has a 5-year average return on invested capital (ROIC) of -61.1%. This is below average and may indicate limited pricing power.
Dianthus Therapeutics, Inc. /DE/ (DNTH) has a market capitalization of $5.7B. It is classified as a mid-cap stock.
Dianthus Therapeutics, Inc. /DE/ (DNTH) does not currently pay a regular dividend.
Dianthus Therapeutics, Inc. /DE/ (DNTH) operates in the Pharmaceutical Preparations industry, within the Healthcare sector.
Dianthus Therapeutics, Inc. /DE/ (DNTH) generated $-129 million in free cash flow in its most recent fiscal year. Negative free cash flow may indicate heavy investment or operational challenges.
Dianthus Therapeutics, Inc. /DE/ (DNTH) has a debt-to-equity ratio of 0.00. This indicates a conservatively financed balance sheet.
Dianthus Therapeutics, Inc. /DE/ (DNTH) reported earnings per share (EPS) of $-4.20 in its most recent fiscal year.
We are a clinical-stage biotechnology company focused on developing next-generation complement therapeutics for patients living with severe autoimmune and inflammatory diseases. We believe our lead novel and proprietary monoclonal antibody product candidate, DNTH103, has the potential to address a broad array of complement-dependent diseases as currently available therapies and those in development leave room for improvements in efficacy, safety, and/or dosing convenience. We have purposefully engineered DNTH103 to selectively bind to only the active form of the C1s complement protein (“C1s”) and to exhibit improved potency and an extended half-life. By selectively targeting only the active form of C1s, which drives disease pathology and constitutes only a small fraction of the total protein present in circulation, we aim to reduce the amount of drug required for a therapeutic effect.
| Metric | TTM | FY2025 | FY2024 | FY2023 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|
| Revenue | 1.7M | - | - | - | 0 | 0 |
| Net Income | -174M | -162M | -85M | -44M | -77M | -58M |
| EPS | $-4.08 | $-4.20 | $-2.55 | $-1.47 | $-4.14 | $-6.26 |
| Free Cash Flow | -130M | -129M | -78M | -37M | -60M | -50M |
| ROIC | -167.8% | -38.4% | -32.6% | -69.8% | -53.5% | -111.3% |
| Gross Margin | - | 0.0% | - | - | - | - |
| Debt/Equity | 0.00 | 0.00 | 0.00 | 0.01 | 0.14 | 0.08 |
| Dividends/Share | $0.00 | $0.00 | $0.00 | $0.00 | - | - |
| Operating Income | -191M | -178M | -102M | -48M | -83M | -60M |
| Operating Margin | -11108.5% | 0.0% | - | - | - | - |
| ROE | -14.5% | -38.4% | -32.6% | -70.0% | -53.5% | -111.3% |
| Shares Outstanding | 55M | 39M | 33M | 30M | 19M | 9M |
| Metric | ||||||||
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | 0 | 0 | 0 | 0 | N/A | N/A | N/A | 1.7M |
| Gross Margin | 0.0% | N/A | N/A | N/A | N/A | N/A | 0.0% | N/A |
| R&D | 5.8M | 28M | 41M | 59M | 33M | 83M | 146M | 153M |
| SG&A | 3.5M | 7.8M | 19M | 24M | 18M | 25M | 34M | 39M |
| EBIT | -9.3M | -36M | -60M | -83M | -48M | -102M | -178M | -191M |
| Op. Margin | 0.0% | N/A | N/A | N/A | N/A | N/A | 0.0% | -11108.5% |
| Net Income | N/A | -36M | -58M | -77M | -44M | -85M | -162M | -174M |
| Net Margin | 0.0% | N/A | N/A | N/A | N/A | N/A | 0.0% | -10084.8% |
| Non-Recurring | 0 | 0 | -67K | 0 | 0 | 0 | 0 | 0 |
| Returns on Capital | ||||||||
| ROIC | N/A | -65.6% | -111.3% | -53.5% | -69.8% | -32.6% | -38.4% | -167.8% |
| ROE | N/A | 139.3% | -111.3% | -53.5% | -70.0% | -32.6% | -38.4% | -14.5% |
| ROA | N/A | -130.3% | -54.4% | -48.2% | -33.2% | -30.7% | -35.9% | -13.9% |
| Cash Flow | ||||||||
| Op. Cash Flow | -6.5M | -22M | -42M | -57M | -37M | -78M | -129M | -130M |
| Free Cash Flow | -6.7M | -24M | -50M | -60M | -37M | -78M | -129M | -130M |
| Owner Earnings | -7.2M | -25M | -53M | -69M | -40M | -91M | -152M | -159M |
| CapEx | 139K | 2.2M | 7.7M | 3.1M | 110K | 105K | 213K | 199K |
| Maint. CapEx | 6K | 376K | 875K | 1.8M | 97K | 193K | 304K | 420K |
| Growth CapEx | 133K | 1.8M | 6.8M | 1.2M | 13K | 0 | 0 | 0 |
| D&A | 6K | 376K | 875K | 1.8M | 97K | 193K | 304K | 420K |
| CapEx/OCF | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 0.0% |
| Capital Allocation | ||||||||
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Dividend Yield | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Buyback Yield | 0.0% | N/A | N/A | N/A | N/A | N/A | 0.0% | 0.0% |
| Stock-Based Comp | 662K | 2.3M | 11M | 10M | 2.9M | 13M | 23M | 28M |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Balance Sheet | ||||||||
| Net Debt | 2.0M | N/A | N/A | N/A | -173M | -274M | -403M | -1.1B |
| Cash & Equiv. | 4.5M | 51M | 58M | 65M | 132M | 23M | 51M | 1.1B |
| Long-Term Debt | 6.5M | N/A | N/A | N/A | 377K | 0 | N/A | N/A |
| Debt/Equity | -0.73 | -0.10 | 0.08 | 0.14 | 0.01 | 0.00 | 0.00 | 0.00 |
| Interest Coverage | -56.9 | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Equity | -8.9M | -42M | 146M | 141M | 169M | 352M | 493M | 1.2B |
| Total Assets | 41K | 54M | 157M | 162M | 179M | 374M | 531M | 1.2B |
| Total Liabilities | 8.9M | 4.1M | 12M | 20M | 11M | 22M | 38M | 46M |
| Intangibles | 0 | N/A | N/A | N/A | N/A | N/A | 0 | 0 |
| Retained Earnings | N/A | -45M | -103M | -179M | -89M | -174M | -337M | -378M |
| Working Capital | N/A | 48M | 135M | 136M | 168M | 262M | 379M | 1.1B |
| Current Assets | N/A | 53M | 145M | 150M | 177M | 281M | 409M | 1.1B |
| Current Liabilities | N/A | 4.1M | 10M | 14M | 9.6M | 18M | 31M | 38M |
| Per Share Data | ||||||||
| EPS | -130.30 | -38.24 | -6.26 | -4.14 | -1.47 | -2.55 | -4.20 | -4.08 |
| Owner EPS | N/A | -26.81 | -5.81 | -3.72 | -1.34 | -2.74 | -3.94 | -2.91 |
| Book Value | N/A | -45.36 | 15.83 | 7.61 | 5.70 | 10.58 | 12.77 | 22.01 |
| Cash Flow/Share | N/A | -23.98 | -4.55 | -3.08 | -1.24 | -2.35 | -3.34 | -3.17 |
| Dividends/Share | N/A | N/A | N/A | N/A | 0.00 | 0.00 | 0.00 | 0.00 |
| Shares Out. | N/A | 0.9M | 9.2M | 18.5M | 29.6M | 33.3M | 38.7M | 54.6M |
| Valuation | ||||||||
| P/E Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A | -25.5 |
| P/FCF | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| EV/EBIT | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Price/Book | N/A | N/A | 11.5 | 61.5 | 1.9 | 2.1 | N/A | 4.7 |
| Price/Sales | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| FCF Yield | N/A | N/A | -3.0% | -0.7% | -11.4% | -10.3% | N/A | -2.3% |
| Market Cap | 0 | N/A | 1.7B | 8.7B | 325M | 758M | 0 | 5.7B |
| Avg. Price | 0.00 | N/A | 176.79 | 198.07 | 11.47 | 24.84 | 0.00 | 103.87 |
| Year-End Price | 0.00 | N/A | 91.20 | 234.24 | 10.13 | 22.74 | 0.00 | 103.87 |
Dianthus Therapeutics, Inc. /DE/ passes 0 of 9 quality checks, indicating weak fundamentals.
Dianthus Therapeutics, Inc. /DE/ (DNTH) has a return on equity (ROE) of -38.4%. A negative ROE may indicate losses or negative equity.
The Ledger Terminal provides 7 years of financial data for Dianthus Therapeutics, Inc. /DE/ (DNTH), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
Dianthus Therapeutics, Inc. /DE/ (DNTH) has a book value per share of $12.77, based on its most recent annual SEC filing.
No recent press releases.